XGX Pharma ApS: Financial statements 2019
CVR: 32289290
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 11,716,951 and a net result of DKK 8,356,668 compared with DKK 26,878 the year before. That is an increase of 644% compared with the year before. Equity in the 2019 report amounted to DKK 11,416,015. The solvency ratio was 60.8%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 11,716,951
- Profit/Loss
- DKK 8,356,668
- Equity
- DKK 11,416,015
- Total Assets
- DKK 18,775,516
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 11.7 mio. | 8.4 mio. | 11.4 mio. | 3 |
| 2018 | - | 1.6 mio. | 27 t. | 59 t. | 1 |
| 2017 | - | 104 t. | -189 t. | 32 t. | - |
| 2016 | - | 307 t. | 272 t. | 92 t. | - |
| 2015 | - | -33 t. | -35 t. | -180 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of November 22, 2019, Lars Karlsmose has joined the board of directors of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2018. Gross profit came to DKK 1,574,797, and the net result was DKK 26,878.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named VITAL PHARMA NORDIC ApS and VITAL PHARMA NORDIC HOLDING ApS. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.